Marketing and manufacturing approval received for TENELIA(R) 20mg tablets
29 June 2012 | By Daiichi Sankyo
A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan...
List view / Grid view
29 June 2012 | By Daiichi Sankyo
A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan...
11 June 2012 | By Daiichi Sankyo
Daiichi Sankyo Group’s leading antihypertensive franchise olmesartan medoxomil launched...
22 May 2012 | By Daiichi Sankyo
This agreement is designed to integrate the high-level cancer research technology...
20 February 2012 | By Daiichi Sankyo
The European Commission has approved Zelboraf® (vemurafenib)...
18 January 2012 | By Daiichi Sankyo
RANMARK (denosumab), a treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors...
16 January 2012 | By Weber Shandwick
Enrolment of the first patient into the PREvention oF thromboembolic events...
8 November 2011 | By Daiichi Sankyo
Basic agreement reached for activities in Brazil related to the development and marketing of Imidafenacin...
1 November 2011 | By Daiichi Sankyo
Daiichi Sankyo has established a new Japanese vaccine research unit to be located in its Kasai R&D Center...
17 August 2011 | By Daiichi Sankyo
First-in-class treatment option soon available to treat deadly form of skin cancer...
24 May 2011 | By AstraZeneca
AstraZeneca signs agreement with Daiichi Sankyo for denosumab for the treatment of bone disorders...
26 April 2011 | By Daiichi Sankyo
LIXIANA® (Edoxaban) is a direct oral factor Xa inhibitor for the prevention of venous thromboembolism...
29 October 2010 | By AstraZeneca
AstraZeneca announced an agreement with Daiichi Sankyo for the co-promotion and supply of NEXIUM, a proton pump inhibitor...